{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T22:00:11Z","timestamp":1776463211718,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004482","name":"Kuwait University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.biopha.2021.111852","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T21:06:11Z","timestamp":1624914371000},"page":"111852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The novel piperazino-enaminone JOAB-40 reduced colitis severity in mice via inhibition tumor necrosis factor-\u03b1 and interleukin-1\u03b2"],"prefix":"10.1016","volume":"141","author":[{"given":"Maitham A.","family":"Khajah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanaa","family":"Hawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen E.","family":"Szollosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Bill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Ghoneim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Edafiogho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2021.111852_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.suc.2007.03.001","article-title":"Pathophysiology of inflammatory bowel disease: an overview","volume":"87","author":"Thoreson","year":"2007","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.biopha.2021.111852_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.med.51.1.289","article-title":"Role of cytokines in the pathogenesis of inflammatory bowel disease","volume":"51","author":"Papadakis","year":"2000","journal-title":"Annu Rev. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.111852_bib3","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.4049\/jimmunol.159.12.6276","article-title":"A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn\u2019s disease","volume":"159","author":"Plevy","year":"1997","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111852_bib4","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1002\/jps.20967","article-title":"Enaminones: exploring additional therapeutic activities","volume":"96","author":"Edafiogho","year":"2007","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.111852_bib5","first-page":"441","article-title":"Hypertensive effects and structure-activity relationships of 5-omega-aminoalkyl isoxazoles","volume":"43","author":"Dannhardt","year":"1993","journal-title":"Arzneimittelforschung"},{"issue":"17","key":"10.1016\/j.biopha.2021.111852_bib6","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1021\/jm970266p","article-title":"Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease","volume":"40","author":"Dom\u00ednguez","year":"1997","journal-title":"J. Med Chem."},{"issue":"8","key":"10.1016\/j.biopha.2021.111852_bib7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0223-5234(02)01377-6","article-title":"Synthesis and anticonvulsant activity of enaminones. 4. Investigations on isoxazole derivatives","volume":"37","author":"Eddington","year":"2002","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.biopha.2021.111852_bib8","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1021\/jm00093a012","article-title":"Synthesis and anticonvulsant activity of enaminones","volume":"35","author":"Edafiogho","year":"1992","journal-title":"J. Med. Chem."},{"issue":"11\u201312","key":"10.1016\/j.biopha.2021.111852_bib9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.lfs.2011.07.007","article-title":"Anti-tussive and bronchodilator mechanisms of action for the enaminone E121","volume":"89","author":"El-Hashim","year":"2011","journal-title":"Life Sci."},{"issue":"1\u20133","key":"10.1016\/j.biopha.2021.111852_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2009.12.004","article-title":"Anti-inflammatory and immunosuppressive effects of the enaminone E121","volume":"632","author":"El-Hashim","year":"2010","journal-title":"Eur. J. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2021.111852_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168567","article-title":"Anti-inflammatory properties of the enaminone E121 in the dextran sulfate sodium (DSS) colitis model","volume":"11","author":"Khajah","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.biopha.2021.111852_bib12","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1016\/j.bmcl.2012.04.118","article-title":"The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity","volume":"22","author":"Cumming","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.biopha.2021.111852_bib13","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s10753-016-0443-y","article-title":"Novel piperazino-enaminones suppress pro-inflammatory cytokines and inhibit chemokine receptor CCR2","volume":"39","author":"Szollosi","year":"2016","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.biopha.2021.111852_bib14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0968-0896(01)00314-5","article-title":"Ultraviolet spectroscopy of anticonvulsant enaminones","volume":"10","author":"Edafiogho","year":"2002","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2021.111852_bib15","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0968-0896(99)00185-6","article-title":"Synthesis, characterization and anticonvulsant activity of enaminones. Part 6: synthesis of substituted vinylic benzamides as potential anticonvulsants","volume":"7","author":"Foster","year":"1999","journal-title":"Bioorg. Med. Chem."},{"issue":"14","key":"10.1016\/j.biopha.2021.111852_bib16","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1021\/jm00066a003","article-title":"Synthesis and anticonvulsant activity of enaminones. 2. Further structure-activity correlations","volume":"36","author":"Scott","year":"1993","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.biopha.2021.111852_bib17","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1021\/jm00020a019","article-title":"Synthesis and anticonvulsant activity of enaminones. 3. Investigations on 4\u2019-, 3\u2019-, and 2\u2019-substituted and polysubstituted anilino compounds, sodium channel binding studies, and toxicity evaluations","volume":"38","author":"Scott","year":"1995","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.biopha.2021.111852_bib18","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.bmc.2018.06.003","article-title":"Design, synthesis and biological evaluation of piperazino-enaminones as novel suppressants of pro-Inflammatory cytokines","volume":"26","author":"Ghoneim","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111852_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150861","article-title":"Anti-inflammatory action of angiotensin 1-7 in experimental colitis","volume":"11","author":"Khajah","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2021.111852_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nprot.2007.41","article-title":"Chemically induced mouse models of intestinal inflammation","volume":"2","author":"Wirtz","year":"2007","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.biopha.2021.111852_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00054725-199802000-00009","article-title":"The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn\u2019s disease","volume":"4","author":"MacDermott","year":"1998","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.biopha.2021.111852_bib22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.4049\/jimmunol.156.6.2095","article-title":"Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro","volume":"156","author":"Taub","year":"1996","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111852_bib23","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/gut.2003.028225","article-title":"CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn\u2019s disease","volume":"53","author":"Connor","year":"2004","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.biopha.2021.111852_bib24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/intimm\/dxh284","article-title":"The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis","volume":"17","author":"Tokuyama","year":"2005","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111852_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0016-5085(95)90006-3","article-title":"Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa","volume":"108","author":"Reinecker","year":"1995","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.biopha.2021.111852_bib26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/gut.44.5.629","article-title":"Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa","volume":"44","author":"Wedemeyer","year":"1999","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.biopha.2021.111852_bib27","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.4049\/jimmunol.164.12.6303","article-title":"Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine","volume":"164","author":"Andres","year":"2000","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111852_bib28","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s10753-019-01032-y","article-title":"Novel piperazino-enaminones decrease pro-inflammatory cytokines following hemarthrosis in a hemophilia mouse model","volume":"42","author":"Zhong","year":"2019","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.biopha.2021.111852_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/gast.2002.30770","article-title":"Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn\u2019s disease","volume":"122","author":"Hommes","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2021.111852_bib30","first-page":"3","article-title":"Anti-inflammatory and anti-oxidative activities of paeonol and its metabolites through blocking MAPK\/ERK\/p38 signaling pathway","volume":"2015","author":"Jin","year":"2015","journal-title":"Inflammation"},{"issue":"20","key":"10.1016\/j.biopha.2021.111852_bib31","doi-asserted-by":"crossref","first-page":"6180","DOI":"10.3748\/wjg.v21.i20.6180","article-title":"SGK1 inhibits cellular apoptosis and promotes proliferation via the MEK\/ERK\/p53 pathway in colitis","volume":"21","author":"Bai","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111852_bib32","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ajpath.2015.05.020","article-title":"Insulin-like growth factor-1 contributes to mucosal repair by beta-arrestin2-mediated extracellular signal-related kinase signaling in experimental colitis","volume":"185","author":"Chen","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111852_bib33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/BF01300378","article-title":"Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease","volume":"37","author":"Stevens","year":"1992","journal-title":"Dig. Dis. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2021.111852_bib34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1023\/A:1018895500721","article-title":"Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies","volume":"42","author":"Dionne","year":"1997","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.111852_bib35","first-page":"387","article-title":"Cytokine expression in intestinal mucosal biopsies. In situ hybridisation of the mRNA for interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha in inflammatory bowel disease","volume":"5","author":"Woywodt","year":"1994","journal-title":"Eur. Cytokine Netw."},{"issue":"6","key":"10.1016\/j.biopha.2021.111852_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/jcla.1860080618","article-title":"Cytokine production in whole blood cell cultures of patients with Crohn\u2019s disease and ulcerative colitis","volume":"8","author":"Els\u00e4sser-Beile","year":"1994","journal-title":"J. Clin. Lab Anal."},{"issue":"1","key":"10.1016\/j.biopha.2021.111852_bib37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","article-title":"Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn\u2019s disease","volume":"94","author":"Reinecker","year":"1993","journal-title":"Clin. Exp. Immunol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100634X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100634X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:20:30Z","timestamp":1776460830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222100634X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":37,"alternative-id":["S075333222100634X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111852","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel piperazino-enaminone JOAB-40 reduced colitis severity in mice via inhibition tumor necrosis factor-\u03b1 and interleukin-1\u03b2","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111852"}}